172 related articles for article (PubMed ID: 36630514)
1. Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma.
Uslu U; Da T; Assenmacher CA; Scholler J; Young RM; Tchou J; June CH
Sci Adv; 2023 Jan; 9(2):eade2526. PubMed ID: 36630514
[TBL] [Abstract][Full Text] [Related]
2. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor-T Cell Therapy Decreases Distant Metastasis and Inhibits Local Recurrence Post-surgery in Mice.
Li D; Jiang L; Zhou W; Huang Y; Yang Y; Li J; Yang J; Wang F; Li J; Zhang Y; Yan F; Gao H; Guo X; Xu Q; Tan S; Wei YQ; Wang W
Hum Gene Ther; 2023 Dec; 34(23-24):1248-1256. PubMed ID: 37917093
[TBL] [Abstract][Full Text] [Related]
4. A rational mouse model to detect on-target, off-tumor CAR T cell toxicity.
Castellarin M; Sands C; Da T; Scholler J; Graham K; Buza E; Fraietta JA; Zhao Y; June CH
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32544101
[TBL] [Abstract][Full Text] [Related]
5. The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better.
Mao R; Kong W; He Y
Front Immunol; 2022; 13():1032403. PubMed ID: 36325345
[TBL] [Abstract][Full Text] [Related]
6. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.
Li K; Xu J; Wang J; Lu C; Dai Y; Dai Q; Zhang W; Xu C; Wu S; Kang Y
Cancer Immunol Immunother; 2023 Apr; 72(4):917-928. PubMed ID: 36166071
[TBL] [Abstract][Full Text] [Related]
7. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
[TBL] [Abstract][Full Text] [Related]
8. CARTs for Solid Tumors: Feasible or Infeasible?
Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.
Holland EM; Yates B; Steinberg SM; Yuan CM; Wang HW; Annesley C; Shalabi H; Stroncek D; Fry TJ; Krueger J; Jacoby E; Hsieh E; Bhojwani D; Gardner RA; Maude SL; Shah NN
Transplant Cell Ther; 2023 Sep; 29(9):574.e1-574.e10. PubMed ID: 37394115
[TBL] [Abstract][Full Text] [Related]
10. Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC.
Caraballo Galva LD; Jiang X; Hussein MS; Zhang H; Mao R; Brody P; Peng Y; He AR; Kehinde-Ige M; Sadek R; Qiu X; Shi H; He Y
Hepatology; 2022 Aug; 76(2):330-344. PubMed ID: 34897774
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
12. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
13. Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in mice.
Zhou X; Yang M; Yu J; Tan J; Xu N; Zhou Y; Zhang W; Ma J; Zhang Z; Friedlaender A; Taylor J; Yu L; Yan Z
J Gastrointest Oncol; 2024 Feb; 15(1):312-329. PubMed ID: 38482238
[TBL] [Abstract][Full Text] [Related]
14. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR; Tanyi JL; O'Hara MH; Gladney WL; Lacey SF; Torigian DA; Soulen MC; Tian L; McGarvey M; Nelson AM; Farabaugh CS; Moon E; Levine BL; Melenhorst JJ; Plesa G; June CH; Albelda SM; Beatty GL
Mol Ther; 2019 Nov; 27(11):1919-1929. PubMed ID: 31420241
[TBL] [Abstract][Full Text] [Related]
15. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients.
Didolkar MS; Coleman CW; Brenner MJ; Chu KU; Olexa N; Stanwyck E; Yu A; Neerchal N; Rabinowitz S
J Gastrointest Surg; 2010 Oct; 14(10):1547-59. PubMed ID: 20839073
[TBL] [Abstract][Full Text] [Related]
16. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.
Lv J; Zhao R; Wu D; Zheng D; Wu Z; Shi J; Wei X; Wu Q; Long Y; Lin S; Wang S; Wang Z; Li Y; Chen Y; He Q; Chen S; Yao H; Liu Z; Tang Z; Yao Y; Pei D; Liu P; Zhang X; Zhang Z; Cui S; Chen R; Li P
J Hematol Oncol; 2019 Feb; 12(1):18. PubMed ID: 30777106
[TBL] [Abstract][Full Text] [Related]
17. Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer.
Makita Y; Kunii N; Sakurai D; Ihara F; Motohashi S; Suzuki A; Nakayama T; Okamoto Y
BMC Cancer; 2018 Dec; 18(1):1254. PubMed ID: 30558663
[TBL] [Abstract][Full Text] [Related]
18. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
Baroni ML; Sanchez Martinez D; Gutierrez Aguera F; Roca Ho H; Castella M; Zanetti SR; Velasco Hernandez T; Diaz de la Guardia R; Castaño J; Anguita E; Vives S; Nomdedeu J; Lapillone H; Bras AE; van der Velden VHJ; Junca J; Marin P; Bataller A; Esteve J; Vick B; Jeremias I; Lopez A; Sorigue M; Bueno C; Menendez P
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32527933
[TBL] [Abstract][Full Text] [Related]
19. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
Goto S; Sakoda Y; Adachi K; Sekido Y; Yano S; Eto M; Tamada K
Cancer Immunol Immunother; 2021 Sep; 70(9):2503-2515. PubMed ID: 33559069
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer.
Li Y; Xiao F; Zhang A; Zhang D; Nie W; Xu T; Han B; Seth P; Wang H; Yang Y; Wang L
Cell Immunol; 2020 Feb; 348():104041. PubMed ID: 31983398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
